Bikaji Foods grows FY26 revenue by 11.5% to ₹2,758 crore
Net profit rose 28% to ₹269 crore as the company sticks to a final dividend of ₹1.25 per share.
— 1 earlier story on Bikaji Foods International Ltd. →What's new with Bikaji Foods International Ltd.
- Revenue reached ₹2,758 crore for FY26, an 11.5% increase.
- Net profit hit ₹269 crore, up 28% from the prior year.
- The board proposed a final dividend of ₹1.25 per share, unchanged from the previous year.
Why this matters for Bikaji Foods International Ltd.
The results track as a routine performance update with no material deviations from established business strategy. The firm's focus remains on maintaining steady shareholder payouts while managing its existing portfolio of subsidiary and manufacturing investments.
What we're watching
- Realization of revenue growth from recent capacity expansions.
- Margins in subsequent quarters given the current investment phase.
- Updates on the integration of Jai Barbareek Dev Snacks.
The full read
Bikaji Foods ended **FY26** with revenue of **₹2,758 crore**, a **11.5%** increase over the previous year. Net profit followed a stronger trajectory, climbing **28%** to **₹269 crore**. Shareholders will see a dividend of **₹1.25** per share, keeping payouts level with last year. The regulatory filing provides a procedural wrap-up for the fiscal year, confirming results that align with the company's previously announced investment trajectory. There are no surprises here. The board's agenda focused on validating existing commitments, such as the capital infusion for its US subsidiary and the **74%** stake in Jai Barbareek Dev Snacks. Having already cleared these structural moves in earlier meetings, the company is now focused on the execution phase of its expansion plan. The numbers confirm the firm's current growth path, leaving no new material questions for the market to reconcile.
Questions answered
- What is the final dividend for FY26?
- The board has recommended a final dividend of ₹1.25 per share.
- Did the filing disclose new strategic investments?
- No, all disclosed investments like the US subsidiary infusion and the Jai Barbareek stake were already public.